Updated median PFS and analysis of quality of life (QOL) in optimal, a phase III, randomized, open-label, first line study of erlotinib vs carboplatin/gemcitabine in patients with advanced nonsmall cell lung cancer (NSCLC) with EGFR activating mutations

Category Primary study
JournalJournal of Thoracic Oncology
Year 2011
This article has no abstract
Epistemonikos ID: e24384a6c9943fe4f22f5536bf701dfcb7a20f37
First added on: Feb 05, 2025